Lung cancer screening: Current situation and perspective

Swiss Medical Weekly

Volumn 137, Issue 21-22, 2007, Pages 304-311

  Guessous, Idris ^a,c   Cornuz, Jacques ^b   Paccaud, Fred ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Low dose CT; Lung cancer; Lung cancer screening; Smoking cessation; X ray

Indexed keywords

BIOLOGICAL MARKER;

CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INCIDENCE; LUNG CANCER; REVIEW; SMOKING; SMOKING CESSATION; SPUTUM ANALYSIS; SPUTUM EXAMINATION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; THORAX RADIOGRAPHY;

EID: 34347326310     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Gohagan J, Marcus P, Fagerstrom R, Pinsky P, Kramer B, Prorok P. Writing Committee, Lung Screening Study Research Group. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest. 2004;126:114-21.
2. Jett JR, Midthun DE. Screening for lung cancer: current status and future directions: Thomas A. Neff lecture. Chest. 2004;125:158S-62S.
3. American Cancer Society. Cancer facts and figures: 1999. Atlanta, GA: Am Cancer Soc. 1999;1-36.
4. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 2000;321:323-9.
5. Wilson JMP, Jungner G. Principles and Practice of Screening for Disease. Geneva, Switzerland, World Health Organization, 1968. Public Health Papers, number 39.
6. van Klaveren RJ, Habbema JDF, Pedersen JH, de Koning HJ, Oudkerk M, Hoogsteden HC. Lung cancer screening by low-dose spiral computed tomography. Eur Respir J. 2001;18:857-66.
7. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33-64.
8. Robert E. Swaney III. Primary Care Case Reviews. 2002;4:157-66.
9. Levi F, Lucchini F, La Vecchia C, Negri E. Trends in mortality from cancer in the European Union, 1955-94. Lancet. 1999;354:742-3.
10. Brennan P, Bray I. Recent trends and future directions for lung cancer mortality in Europe. Br J Cancer. 2002;87:43-8.
11. Hill C. Trends in tobacco smoking and consequences on health in France. Prev Med. 1998;27:514-9.
12. Remontet L, Esteve J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique. 2003;51:3-30.
13. Giron J, Fajadet P, Senac JP, Durand G, Benezet O, Didier A. Diagnostic percutaneous thoracic punctures. Assessment through a critical study of a compilation of 2406 cases. Rev Mal Respir. 1996;13:583-90.
14. Gossot D, de Kerviler E, Paladines G, Frija J, Celerier M. Thoracoscope approach in pulmonary nodules: a prospective evaluation of a series of 120 patients. Rev Mal Respir. 1997;14:287-93.
15. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-7.
16. Sobue T, Suzuki T, Matsuda M, Kuroishi T, Ikeda S, Naruke T. Survival for clinical stage I lung cancer not surgically treated. Comparison between screen-detected and symptom-detected cases. The Japanese Lung Cancer Screening Research Group. Cancer. 1992;69:685-92.
17. Humphrey LL, Teutsch S, Johnson M. U.S. Preventive Services Task Force. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140:740-53.
18. Patz EF Jr, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med. 2000;343:1627-33.
19. Frost JK, Ball WC Jr, Levin ML, Tockman MS, Baker RR, Carter D, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis. 1984;130:549-54.
20. Tockman M. Survival and mortality from lung cancer in a screened population: The Johns Hopkins study. Chest. 1986;89:325s-326s.
21. Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest. 1984;86:44-53.
22. Flehinger BJ, Melamed MR, Zaman MB, Heelan RT, Perchick WB, Martini N. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering study. Am Rev Respir Dis. 1984;130:555-60.
23. Fontana RS, Sanderson DR, Taylor WF, Woolner LB, Miller WE, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis. 1984;130:561-5.
24. Flehinger BJ, Kimmel M, Polyak T, Melamed MR. Screening for lung cancer. The Mayo Lung Project revisited. Cancer. 1993;72:1573-80.
25. Kubik A, Polak J. Lung cancer detection. Results of a randomized prospective study in Czechoslovakia. Cancer. 1986;57:2427-37.
26. Kubik AK, Parkin DM, Zatloukal P. Czech Study on Lung Cancer Screening: post-trial follow-up of lung cancer deaths up to year 15 since enrollment. Cancer. 2000;89:2363-8.
27. Manser RL, Irving LB, Byrnes G, Abramson MJ, Stone CA, Campbell DA. Screening for lung cancer: a systematic review and meta-analysis of controlled trials. Thorax. 2003;58:784-9.
28. Kubik A, Parkin DM, Zatioukal P. Czech study on lung cancer screening. Post-trial follow-up of lung cancer death up to year 15 since enrolment. Cancer. 2000;89(Suppl II):2363-8.
29. Marcus P, Bergstrahl EJ, Fagerstrom RM, et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst. 2000;92:1308-16.
30. Petty TL. Sputum cytology for the detection of early lung cancer. Curr Opin Pulm Med. 2003;9:309-12.
31. McWilliams A, Mayo J, MacDonald S, leRiche JC, Palcic B, Szabo E, et al. Lung cancer screening: a different paradigm. Am J Respir Crit Care Med. 2003;168:1167-73.
32. Dalrymple-Hay MJ, Drury NE. Screening for lung cancer. J R Soc Med. 2001;94:2-5.
33. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-7.
34. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 2002;94:1576-8.
35. Mulshine JL, Smith RA. Lung cancer. 2: screening and early diagnosis of lung cancer. Thorax. 2002;57:1071-8.
36. Marcus PM, Fagerstrom RM, Prorok PC, Gohagan JK, Kramer BS. Screening for Lung Cancer with helical CT Scanning. Clin Pulm Med. 2002;9:323-9.
37. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999;354:99-105.
38. Henschke CI, Yankelevitz DF, Libby DM, McCauley D, Pasmantier M, Altorki NK, et al. Early lung cancer action project: annual screening using single-slice helical CT. Ann N Y Acad Sci. 2000;952:124-34.
39. Sone S, Li F, Yang ZG, Honda T, Maruyama Y, Takashima S, et al. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer. 2001;84:25-32.
40. Diederich S, Wormanns D, Semik M, Thomas M, Lenzen H, Roos N, et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology. 2002;222:773-81.
41. Nawa T, Nakagawa T, Kusano S, Kawasaki Y, Sugawara Y, Nakata H. Lung cancer screening using low-dose spiral CT: results of baseline and 1-year follow-up studies. Chest. 2002;122:15-20.
42. Sobue T, Moriyama N, Kaneko M, Kusumoto M, Kobayashi T, Tsuchiya R, et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol. 2002;20:911-20.
43. Swensen SJ, Jett JR, Sloan JA, Midthun DE, Hartman TE, Sykes AM, et al. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med. 2002;165:508-13.
44. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Sloan JA, Sykes AM, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology. 2003;226:756-61.
45. Bach PB, Niewoehner DE, Black WC. American College of Chest Physicians. Screening for lung cancer: the guidelines. Chest. 2003;123:83S-88S.
46. Manhire A, Charig M, Clelland C, Gleeson F, Miller R, Moss H, et al. BTS. Guidelines for radiologically guided lung biopsy. Thorax. 2003;58:920-36.
47. Garg K, Keith RL, Byers T, Kelly K, Kerzner AL, Lynch DA, et al. Randomized controlled trial with low-dose spiral CT for lung cancer screening: feasibility study and preliminary results. Radiology. 2002;225:506-10.
48. Blanchon T, Lukasiewicz-Hajage E, Lemarie E, Milleron B, Brechot JM, Flahault A. Groupe Depiscan. DEPISCAN - a pilot study to evaluate low dose spiral CT scanning as a screening method for bronchial carcinoma. Rev Mal Respir. 2002;19:701-5.
49. The National Lung Screening Trial (NLST). Available at http://cancer.gov/clinicaltrials/view_clinicaltrials.aspx?version= healthprofessional&cdrid=257938&protocolsearchid=451616.
50. The Nederlands-Leuvens Longkanker Screenings Onderzoek (Nelson), trial design and first screening results the Nederlands-Leuvens Longkanker Screenings Onderzoek (Nelson), a prospective randomised clinical trial on lung cancer screening by spiral CT, poster session 2, P-259, Early Detection and Chemoprevention.
51. The Danish Lung Cancer Group, protocol, screening for lung cancer, a randomised controlled screening trial of low-dose CT-scanning, September 2004.
52. Depiscan. Available at http://www.u444.jussieu.fr/depiscan
53. Norstein J. Cancer Registry of Norway, International Cancer Screening Conference, Oslo, Norway-December 2004.
54. Dobson R. Screening trial for lung cancer planned for UK. BMJ. 2000;320:270.
55. National Cancer Research Network. Available at http://www.ncrn.org.uk/ csg/groups.asp?groupID=8
56. Zulueta JF. Proyecto europeo de la deteccion precoz de cancer de pulmon, Clinica Universitaria de Navarra, Pamplona, Spain.
57. Shaham D. Hadassah Medical Organization, Israel. Available at www.hadassah.org.il/English
58. Giunta S. Screening sul tumore del polmone. La TC-spirale "low-dose" nella diagnosi precoce del cancro del polmone in soggetti a rischio. Available at http://www.ifo.it/ifo.3B023B0c.run
59. New York Early Lung Cancer Action Program (NY-ELCAP). Available at http://www.nyelcap.org
60. Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, et al. ACS Prostate Cancer Advisory Committee, ACS Colorectal Cancer Advisory Committee, ACS Endometrial Cancer Advisory Committee. American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001 - testing for early lung cancer detection. CA Cancer J Clin. 2001;51:38-75.
61. Sladden MJ, Ward JE. Do Australian family physicians screen smokers for lung cancer? Chest. 1999;115:725-8.
62. Swenson SJ. Screening for cancer with computed tomography. BMJ. 2003;326:894-5.
63. Sheridan SL, Harris RP, Woolf SH. Shared Decision-Making Workgroup of the U.S. Preventive Services Task Force. Shared decision making about screening and chemoprevention. a suggested approach from the U.S. Preventive Services Task Force. Am J Prev Med. 2004;26:56-66.
64. Strauss GM, Dominioni L, Jett JR, Freedman M, Grannis FW Jr. Como international conference position statement: lung cancer screening for early diagnosis 5 years after the 1998 Varese conference. Chest. 2005;127:1146-51.
65. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233-9.
66. Hackshaw A. EUSOMA review of mammography screening. Ann Oncol. 2003;14:1193-5.
67. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ. 1998;317:559-65.
68. Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology: the essentials, 3rd ed. Lippincott Williams & Wilkins, 1996.
69. van Klaveren RJ, de Koning HJ, Mulshine J, Hirsch FR. Lung cancer screening by spiral CT. What is the optimal target population for screening trials? Lung Cancer. 2002;38:243-52.
70. Kiyohara C, Otsu A, Shirakawa T, Fukuda S, Hopkin J. Genetic polymorphisms and lung cancer susceptibility: A review. Lung cancer. 2002;37:241-56.
71. Henschke CI. International Early Lung Cancer Action Program: Protocol. Available at http://icscreen.med.cornell.edu/ielcap.pdf
72. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21:273S-309S.
73. Oken MM, Marcus PM, Hu P, Beck TM, Hocking W, Kvale PA, et al. PLCO Project Team. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst. 2005;97:1832-9.
74. McFarlane MJ, Feinstein AR, Wells CK. Clinical features of lung cancers discovered as a postmortem "surprise". Chest. 1986;90:520-3.
75. Hakama M, Holli K, Visakorpi T, Pekola M, Kallioniemi OP. Low biological aggressiveness of screen-detected lung cancers may indicate over-diagnosis. Int J Cancer. 1996;66:6-10.
76. Jha P, Chaloupka F. Economics of Tobacco control. London: Oxford University Press, 2000.